RPL14P1

Across TCGA pan-cancer cohorts, RPL14P1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RPL14P1 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RPL14P1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RPL14P1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, GBM, and LSCC are the cancer types where RPL14P1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.736	0.410	.024	4	view →
GBM	DFS	Median	All	0.478	0.265	.042	2	view →
LSCC	DFS	Tertile	II,III,IV	0.443	1.000	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RPL14P1–PDAC (DFS)

Open the PDAC breakdown →